Viatris Statement on Nationwide Settlement to Resolve Opioid-Related Claims

Core Viewpoint - Viatris Inc. has reached a nationwide settlement framework to resolve opioid-related claims, agreeing to pay up to $335 million over nine years to support state and local efforts addressing opioid issues, while maintaining that this settlement does not imply any admission of wrongdoing or liability [1][2]. Group 1: Settlement Details - The settlement amount could reach a maximum of$335 million, with annual payments ranging from approximately $27.5 million to$40 million over a nine-year period [2]. - The company had already accrued an estimate for this potential settlement, which is reflected in its annual report for the year ended December 31, 2024 [2]. Group 2: Commitment to Public Health - The company continues to work on solutions for public health challenges, including manufacturing a generic injectable version of naloxone, a drug for overdose reversal, and a generic buprenorphine/naloxone product for opioid addiction treatment [3]. - Viatris is also developing a novel delivery method for meloxicam, a non-opioid pain medication [3]. Group 3: Company Mission and Operations - The settlement allows the company to focus on its mission of empowering people to live healthier lives and to address unmet patient needs through an expanded innovative portfolio [4]. - Viatris serves approximately 1 billion patients annually with its diverse portfolio of medicines, emphasizing its commitment to global healthcare [4][5].